VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Pacira BioSciences Executive Compensation (FY25)

PCRX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Frank Lee
Latest say-on-pay support
=
June 9, 2026
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Pacira BioSciences

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 11, 2026
6 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Pacira BioSciences brief$500Get the executive brief
Velarion Intel, one year, every company
221 figures on this page: 219 cited to the filing that reported them, 2 calculated from figures it prints. See the citations

More on Pacira BioSciences

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Frank Lee: $15,944,347 → $11,636,917 (27.0% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Pacira BioSciences' chief executive and what were they paid?
Frank Lee, Chief Executive Officer and Director, received $11,636,917 in total compensation for fiscal 2025. Compared with the $15,944,347 reported for fiscal 2024, Lee's total was 27.0% lower.
What was Pacira BioSciences' say-on-pay result?
The say-on-pay proposal drew 59.9% of votes cast for or against in favor at the meeting held June 9, 2026 for fiscal 2025.
Which companies are in Pacira BioSciences' peer group?
The disclosed peer group names ACADIA Pharmaceuticals, Inc., Alkermes plc, Amicus Therapeutics, Inc., ANI Pharmaceuticals, Inc. and Blueprint Medicines Corporation, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Stack
Chief Executive Officer
◇◇◇◇——◇◇
Daryl Gaugler
Chief Operating Officer
◇◇◇◇——◇◇
Anthony Molloy
Chief Legal and Compliance Officer
◇◇◇◇——◇◇
Kristen Williams
Chief Administrative Officer and Secretary
◇◇◇◇——◇— not reconciled
Charles Reinhart III
Chief Financial Officer
◇◇◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kristen Williams
Chief Administrative Officer and Secretary
◇◇◇◇——◇◇
Jonathan Slonin
Chief Medical Officer
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Frank Lee
Chief Executive Officer
◇◇◇◇◇—◇◇
Kristen Williams
Chief Administrative Officer and Secretary
◇◇◇—◇—◇◇
Jonathan Slonin
Chief Medical Officer
◇◇◇◇◇—◇◇
Shawn Cross
Chief Financial Officer
◇◇◇◇——◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Frank Lee
Chief Executive Officer and Director
◇◇◇—◇—◇◇
Brendan Teehan
Chief Commercial Officer
◇◇◇◇◇—◇◇
Jonathan Slonin
Chief Medical Officer
◇◇◇—◇—◇◇
Kristen Williams
Chief Administrative Officer and Secretary
◇◇◇—◇—◇◇
Shawn Cross
Chief Financial Officer
◇◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Brendan TeehanPSU——————◇
Brendan TeehanOPTION——————◇
Frank LeePSU——————◇
Jonathan SloninPSU——————◇
Kristen WilliamsPSU——————◇
Shawn CrossRSU◇——◇——◇
Shawn CrossOPTION◇——◇—◇◇
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Frank LeeOption◇—◇1/3/2034
RSU◇◇——
RSU◇◇——
Shawn CrossOption◇—◇11/4/2034
RSU◇◇——
Brendan TeehanOption◇—◇2/4/2035
RSU◇◇——
Jonathan SloninRSU◇◇——
RSU◇◇——
Option◇—◇6/14/2033
Option◇—◇1/2/2034
RSU◇◇——
RSU◇◇——
Option◇—◇6/8/2032
RSU◇◇——
Kristen WilliamsRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇6/14/2033
RSU◇◇——
Option◇—◇6/8/2032
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Frank Lee
Chief Executive Officer and Director · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Jonathan Slonin
Chief Medical Officer · Terms as described in the company’s compensation discussion
Severance cash amount◇
Benefits continuation on change in control◇
Benefits continuation◇
Kristen Williams
Chief Administrative Officer and Secretary · Terms as described in the company’s compensation discussion
Severance cash amount◇
Shawn Cross
Chief Financial Officer · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Change-in-control base◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Laura Brege
Board chair
◇◇◇———◇
Mark Kronenfeld
◇◇◇———◇
Alethia Young
◇◇◇———◇
Abraham Ceesay
◇◇◇———◇
Michael Yang
◇◇◇———◇
Mark Froimson
◇◇◇———◇
Marcelo Bigal
◇◇◇———◇
Christopher Christie
◇◇◇———◇
Paul Hastings
◇————◇◇
Samit Hirawat, Frank D. Lee, Andreas Wicki and Thomas Wiggans served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Rsus/Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals, Inc. ACAD
  • Alkermes plc ALKS
  • Amicus Therapeutics, Inc. FOLD
  • ANI Pharmaceuticals, Inc. ANIP
  • Blueprint Medicines Corporation BPMC
  • CareDx, Inc. CDNA
  • Corcept Therapeutics, Inc. CORT
  • Dynavax Technologies Corporation DVAX
  • Exelixis, Inc. EXEL
  • Halozyme Therapeutics, Inc. HALO
  • Ionis Pharmaceuticals, Inc. IONS
  • Ironwood Pharmaceuticals, Inc. IRWD
  • Organogenesis Holdings, Inc. ORGO
  • PTC Therapeutics, Inc. PTCT
  • Supernus Pharmaceuticals, Inc. SUPN
  • Travere Therapeutics, Inc. TVTX
  • Ultragenyx Pharmaceutical, Inc. RARE

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 9, 2026=◇◇◇
2024June 10, 2025=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Frank Lee (Chief Executive Officer and Director), FY2025 total compensation $11,636,917 (base salary $935,308) [exec_comp, SEC accession 0001104659-26-050353, filed 2026-04-28]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Pacira BioSciences files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Pacira BioSciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Pacira BioSciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
Pacira BioSciences recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Pacira BioSciences' disclosed peer group is defensible, who names Pacira BioSciences back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
221 figures on this page: 219 cited to the filing that reported them, 2 calculated from figures it prints.
219 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001628280-26-042525
    Proposal 3 — Advisory vote to approve the compensation of the Company’s named executive officers.
  2. 0001104659-26-050353
    Compensation Tables · DIRECTOR COMPENSATION TABLE · Director Compensation · SUMMARY COMPENSATION TABLE
  3. 0001104659-25-041219
    Grants of Plan-Based Awards
  4. 0001396814-25-000089
    Proposal 3 — Advisory vote to approve the compensation of the Company’s named executive officers.
  6. 0001104659-23-048374
    Compensation Tables
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Pacira BioSciences executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/PCRX (accessed 2026).
Short form: data: Velarion

The paid brief for Pacira BioSciences

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Pacira BioSciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Pacira BioSciences discloses

The companies named in PCRX's own disclosed peer group.

ACADIA Pharmaceuticals, Inc.Alkermes plcAmicus Therapeutics, Inc.ANI Pharmaceuticals, Inc.Blueprint Medicines CorporationCareDx, Inc.Corcept Therapeutics, Inc.Dynavax Technologies CorporationExelixis, Inc.Halozyme Therapeutics, Inc.Ionis Pharmaceuticals, Inc.Ironwood Pharmaceuticals, Inc.Organogenesis Holdings, Inc.PTC Therapeutics, Inc.Supernus Pharmaceuticals, Inc.Travere Therapeutics, Inc.Ultragenyx Pharmaceutical, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy